Skip to content

A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Intractable Pain

A Post Market Cohort to Assess the Performance of the Spinal Modulation Neurostimulator System for the Management of Chronic Intractable Pain - Performance of the Spinal Modulation Neurostimulator System

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON37488
Enrollment
80
Registered
2012-04-06
Start date
2012-04-26
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic intractable pain Chronic intractable pain

Interventions

None listed

Sponsors

Spinal Modulation NV
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Subject is at least 18 years old 2.Subject is able and willing to comply with the follow-up schedule and protocol 3.Chronic, intractable pain in the thoracic, lumbar, and/or sacral distribution(s) for at least 6 months 4.Failed conservative treatments for chronic pain including but not limited to pharmacological therapy, physical therapy and interventional pain procedures for chronic pain 5.Minimum baseline pain rating of 60 mm on the VAS in the primary region of pain 6.In the opinion of the investigator, the subject is psychologically appropriate for the implantation for an active implantable medical device 7.Subject is able to provide written informed consent 8.Subject speaks Dutch or English

Exclusion criteria

Exclusion criteria: 1.Female subject of childbearing potential is pregnant/nursing, plans to become pregnant or is unwilling to use approved birth control 2.Escalating or changing pain condition within the past month as evidenced by investigator examination 3.Subject has had corticosteroid therapy at an intended site of stimulation within the past 30 days 4.Subject has had radiofrequency treatment of an intended target DRG(s) within the past 3 months 5.Subject currently has an active implantable device including ICD, pacemaker, spinal cord stimulator or intrathecal drug pump 6.Subject has pain only or primarily within a cervical dermatomal distribution 7.Subject is unable to operate the device 8.Subjects with indwelling devices that may pose an increased risk of infection 9.Subjects currently has an active infection 10.Subject has, in the opinion of the investigator, a medical comorbidity that contraindicates placement of an active medical device 11.Subject has participated in another clinical investigation within 30 days 12.Subject has a coagulation disorder or uses anticoagulants that, in the opinion of the investigator, precludes participation 13.Subject has been diagnosed with cancer in the past 2 years

Design outcomes

Primary

MeasureTime frame
1. Pain relief measured using a Visual Analogue Scale (VAS). 2. Device safety by monitoring occurrence of (S)AEs 3. Quality of life (EQ-5D) 4. Physical functioning (BPI, ODI) 5. Oswestry low back pain disability questionairy 6. Pain distribution 7. Paresthesia distribution 8.Subject satisfaction

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)